The Week in Review: Lilly Has Big Plans for China

Lilly is investing “aggressively” in China and will launch 15 new products in China over the next five years; Teijin Pharma and Astellas have teamed up to promote Teijin’s treatment for gout in China and Hong Kong; China Pharmaceuticals Inc. has completed a reverse merger; AlphaRx will list its Canadian subsidiary on a Canadian exchange; ProMetic Life Sciences completed the first milestone in its technology transfer with a Sinopharm subsidiary; Martek Biosciences is exporting its DHA omega-3 product through COFCO; Quintiles’ China Global Central Lab was accorded the national “Best Central Lab 2009” award by the Shanghai Mental Health Center; Qiagen has created a sponsored professorship in life sciences at the University of Science and Technology of China; and China Aoxing Pharmaceutical Company  (中国奥星药业) dropped the “China” part of its name and announced a 1-for-2 reverse stock split. More details… Stock Symbols: (NYSE: LLY) (TOK: 4503) (OTCBB: CFMI) (OTCBB: ALRX) (TSX: PLI) (NSDQ: MATK) (NSDQ: QGEN) (OTCBB: CAXGD)